Literature DB >> 3875426

Comparison of murine lymphokine-activated killer cells, natural killer cells, and cytotoxic T lymphocytes.

V J Merluzzi.   

Abstract

Precursors and effectors of murine lymphokine-activated killer cells, natural killer cells, and cytotoxic T lymphocytes are compared. Natural killer cells are resistant to gamma-irradiation (1000 R) whereas precursors of lymphokine-activated killer cells and cytotoxic T lymphocytes are sensitive. Lower doses of gamma-irradiation (500 R) remove precursors for cytotoxic T lymphocytes but not lymphokine-activated killer cells. In addition, lymphokine-activated killer cells are regenerated before classical CTL after sublethal doses of gamma-irradiation. Natural killer cells are resistant to anti-Thy 1 and C' and anti-thymocyte serum, but sensitive to anti-asialo GM1 and complement. Precursors of cytotoxic T lymphocytes are sensitive to anti-Thy 1 and complement and anti-thymocyte serum, but are resistant to anti-asialo GM1 and complement. Precursors of lymphokine-activated killer cells are partially sensitive to anti-Thy 1 and complement and anti-thymocyte serum, but are resistant to anti-asialo GM1 and complement. Effector cells of cytotoxic T lymphocytes are sensitive to anti-Thy 1 and complement and resistant to anti-asialo GM1 and complement. Lymphokine-activated killer cell effectors are sensitive to anti-asialo GM1 and complement at 24 hr after activation. These effectors are more closely aligned with classical natural killer effectors. Lymphokine-activated killer effectors, 7 days after activation, are resistant to anti-asialo GM1 and complement and sensitive to anti-Thy 1 and complement. Relationships and differences among these cytotoxic subsets are discussed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3875426     DOI: 10.1016/0008-8749(85)90298-9

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  10 in total

1.  Oligodendrocyte-specific autoreactive T cells using an alpha/beta T-cell receptor kill their target without self restriction.

Authors:  V Jewtoukoff; R Lebar; M A Bach
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

2.  Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia.

Authors:  G R Hill; T Teshima; A Gerbitz; L Pan; K R Cooke; Y S Brinson; J M Crawford; J L Ferrara
Journal:  J Clin Invest       Date:  1999-08       Impact factor: 14.808

3.  Activation of swine peripheral blood lymphocytes with human recombinant interleukin-2.

Authors:  R C Bhagyam; D Jarrett-Zaczek; F G Ferguson
Journal:  Immunology       Date:  1988-08       Impact factor: 7.397

4.  Growth inhibition of Candida albicans by interleukin-2-activated splenocytes.

Authors:  D W Beno; H L Mathews
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

5.  Natural killer cells mediate protection induced by a Salmonella aroA mutant.

Authors:  R Schafer; T K Eisenstein
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

6.  Infection of DBA/2 or C3H/HeJ mice by intraperitoneal injection of vaccinia virus elicits activated macrophages, cytolytic and cytostatic for S91-melanoma tumor cells.

Authors:  R J Natuk; J A Byrne; J A Holowczak
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

7.  Opposite effects of interleukin-2 on normal and transfusion-suppressed healing of experimental intestinal anastomoses.

Authors:  T Tadros; T Wobbes; T Hendriks
Journal:  Ann Surg       Date:  1993-12       Impact factor: 12.969

8.  Overnight incubation of mouse spleen cells in recombinant IL-2 generates cytotoxic cells with NK characteristics from precursors enriched with or devoid of LGL.

Authors:  A Punturieri; F Velotti; M Piccoli; R B Herberman; L Frati; A Santoni
Journal:  Clin Exp Immunol       Date:  1989-01       Impact factor: 4.330

9.  Induction of lymphokine-activated killer cells from nude mouse spleen cells by interleukin-4.

Authors:  I S Tunru; H Suzuki; M Kobayashi
Journal:  Experientia       Date:  1993-01-15

10.  Amelioration of B16F10 melanoma lung metastasis in mice by a combination therapy with indomethacin and interleukin 2.

Authors:  R S Parhar; P K Lala
Journal:  J Exp Med       Date:  1987-01-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.